Drugs / deuteriumremidvir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06749236 | Aug 2025 | — | Vigonvita Life Sciences | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | deuteriumremidvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06749236 ↗ |
| Known as | deuteriumremidvir hydrobromide | “Participants will receive a single dose of the test formulation(T) (one bag of 200 mg deuteriumremidvir hydrobromide for suspension).” NCT06749236 ↗ |
| Route | Oral | “oral deuteriumremidvir hydrobromide for suspension” NCT06749236 ↗ |